Table 1.

Model Inputs

Patient Classification Parameters (%)
Percentage of patients that undergo MRSA screening on admission	87.5	Cambridge University Data
Proportion of patients MRSA positive following screening	1.1	Cambridge University Data
Proportion of patients MRSA positive not screened	1.1	Assumed equal to above due to an absence of data
Probability MRSA-positive patient has symptomatic MRSA versus asymptomatic MRSA	14.1	Cambridge University Data
Effectiveness inputs (%)
Probability of MRSA-negative patient acquiring MRSA during their stay (CP)	0.5	Assumption
Reduction in MRSA acquisition due to genome sequencing	90	Assumption
Quality of life and mortality inputs
Quality of life decrement associated with symptomatic MRSA	0.35	US decision analytic model [19]
Proportion of symptomatic MRSA patients that die before discharge due to MRSA infection (%)	4.6	US cost study [10]
Proportion of asymptomatic MRSA patients that die before discharge due to MRSA colonization (%)	0	Assumption
Costs inputs (£)
Cost per case of symptomatic MRSA	17 238	Kunori et al [12]
Cost per case of asymptomatic MRSA	386.80	Canadian decision tree [11]
Cost per genome sequenced	100	A descriptive study of WGS for MRSA [4]
Cost per screen positive	8.19	UK model. Robotham et al [14]
Cost per screen negative	4.79	UK model. Robotham et al[14]
Cost per clinical sample	3.62	UK model. Robotham et al [14]

Abbreviations: CP, current practice; MRSA, methicillin-resistant Staphylococcus aureus; WGS, whole-genome sequencing.